Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab vs Chemotherapy in Pediatric High-Risk First Relapse B-precursor ALL
NCT02393859Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2015
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Started Nov 2015; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02393859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393859.